MeSH term
Frequency | Condition_Probility | Humans | 164 | 0.0 |
Adult | 35 | 0.0 |
Female | 63 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Male | 59 | 0.0 |
Pregnancy | 9 | 0.0 |
Aged | 19 | 0.0 |
Globus Pallidus/physiopathology/surgery | 2 | 100.0 |
Middle Aged | 31 | 0.0 |
Research Support, Non-U.S. Gov't | 87 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 26 | 0.0 |
Animals | 61 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
Glucose-6-Phosphate Isomerase/genetics/immunology/*metabolism | 2 | 100.0 |
Mice | 19 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Base Sequence | 12 | 0.0 |
Molecular Sequence Data | 16 | 0.0 |
Comparative Study | 30 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Variation (Genetics) | 5 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
Arthritis, Rheumatoid/*immunology | 4 | 1.0 |
Autoantibodies/*immunology | 3 | 1.0 |
Autoantigens/immunology | 2 | 1.0 |
Glucose-6-Phosphate Isomerase/*immunology | 7 | 100.0 |
Aged, 80 and over | 6 | 0.0 |
Arthritis, Rheumatoid/immunology | 2 | 2.0 |
Autoantibodies/*blood | 2 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Prognosis | 4 | 0.0 |
Prospective Studies | 2 | 0.0 |
Adolescent | 17 | 0.0 |
Child | 16 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Erythrocytes/enzymology | 10 | 2.0 |
Glycolysis | 4 | 7.0 |
Mutation | 8 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Cross Reactions | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 8 | 0.0 |
Osteoarthritis/immunology | 2 | 10.0 |
Spondylitis, Ankylosing/immunology | 2 | 15.0 |
Synovial Fluid/*immunology | 2 | 3.0 |
Binding Sites | 7 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
DNA Primers | 4 | 0.0 |
Glucose-6-Phosphate Isomerase/*genetics | 8 | 72.0 |
Metaphase | 2 | 1.0 |
Transcription, Genetic | 3 | 0.0 |
Hamsters | 12 | 0.0 |
Neutralization Tests | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Reference Values | 4 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Glucose-6-Phosphate Isomerase/*deficiency/genetics | 5 | 100.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Enzyme Stability | 2 | 1.0 |
Point Mutation | 5 | 0.0 |
Genotype | 2 | 0.0 |
Glucose-6-Phosphate Isomerase/*deficiency/*genetics | 2 | 100.0 |
Gene Frequency | 3 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Cattle/*genetics | 2 | 1.0 |
*Chromosome Mapping | 7 | 0.0 |
Hybrid Cells | 5 | 0.0 |
Chronic Disease | 2 | 0.0 |
Energy Metabolism | 2 | 1.0 |
Erythrocytes/*enzymology/metabolism | 2 | 28.0 |
English Abstract | 10 | 0.0 |
Isoenzymes/*analysis | 11 | 22.0 |
Mesocricetus | 2 | 1.0 |
Anemia, Hemolytic/*enzymology/genetics | 2 | 40.0 |
*Chromosomes, Human, Pair 19 | 4 | 1.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Isoelectric Focusing | 6 | 1.0 |
Phenotype | 6 | 0.0 |
Rats | 3 | 0.0 |
Cells, Cultured | 4 | 0.0 |
Chromatography, Affinity | 3 | 0.0 |
Hela Cells | 3 | 0.0 |
Anemia, Hemolytic/enzymology/*genetics | 2 | 40.0 |
Child, Preschool | 8 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Pedigree | 8 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Glycoproteins/*immunology | 4 | 5.0 |
Electrophoresis, Starch Gel | 14 | 10.0 |
Isoenzymes/*analysis/genetics | 2 | 25.0 |
*Variation (Genetics) | 8 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Consensus Sequence | 2 | 0.0 |
Exons | 4 | 0.0 |
Introns | 4 | 0.0 |
Leukocytes/enzymology | 5 | 4.0 |
Restriction Mapping | 5 | 0.0 |
Swine | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Herpesvirus 3, Human/*metabolism | 2 | 50.0 |
Transfection | 2 | 0.0 |
Cattle | 2 | 0.0 |
Feces/parasitology | 5 | 11.0 |
Glucose-6-Phosphate Isomerase/isolation & purification | 2 | 100.0 |
Hexokinase/isolation & purification | 2 | 100.0 |
Phosphoglucomutase/isolation & purification | 2 | 100.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 3 | 7.0 |
Retrospective Studies | 2 | 0.0 |
Antibodies/*blood | 2 | 4.0 |
Antibodies, Anticardiolipin/*blood | 2 | 13.0 |
Lupus Coagulation Inhibitor/*blood | 2 | 15.0 |
Glucose-6-Phosphate Isomerase/*deficiency | 7 | 100.0 |
Anemia, Hemolytic, Congenital/*enzymology | 2 | 22.0 |
Glucose-6-Phosphate Isomerase/blood/*deficiency/genetics | 3 | 100.0 |
Genes, Structural | 2 | 0.0 |
Species Specificity | 7 | 0.0 |
Antibodies, Anticardiolipin/*analysis | 2 | 33.0 |
Glycoproteins/*physiology | 4 | 6.0 |
Family Health | 2 | 0.0 |
Glucose-6-Phosphate Isomerase/blood/*deficiency | 2 | 100.0 |
Hemoglobins/analysis | 2 | 0.0 |
Glucose-6-Phosphate Isomerase/metabolism | 3 | 60.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
*Disease Models, Animal | 2 | 0.0 |
Glucose-6-Phosphate Isomerase/genetics | 5 | 45.0 |
Mice, Mutant Strains | 2 | 0.0 |
Trophoblasts/pathology | 2 | 33.0 |
Crosses, Genetic | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Swine/*genetics | 2 | 1.0 |
Bilirubin/blood | 2 | 2.0 |
Hematocrit | 2 | 0.0 |
Heterozygote | 4 | 0.0 |
Homozygote | 3 | 0.0 |
Mice, Inbred C3H | 3 | 0.0 |
Spleen/pathology | 2 | 2.0 |
Isoenzymes/*metabolism | 3 | 1.0 |
*Disease Reservoirs | 4 | 16.0 |
Electrophoresis, Cellulose Acetate | 5 | 12.0 |
Isoenzymes/analysis | 10 | 17.0 |
Polymorphism, Genetic | 3 | 0.0 |
Psychodidae/*parasitology | 2 | 100.0 |
Chromosome Mapping | 7 | 0.0 |
Alleles | 5 | 0.0 |
*Genetic Markers | 3 | 0.0 |
Phosphogluconate Dehydrogenase/genetics | 2 | 7.0 |
Venezuela | 2 | 6.0 |
Linkage (Genetics) | 5 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Glucose-6-Phosphate Isomerase/*metabolism | 4 | 66.0 |
Lymphatic Metastasis | 3 | 0.0 |
Cell Line | 7 | 0.0 |
Plasmids | 3 | 0.0 |
Infant | 3 | 0.0 |
Glucose-6-Phosphate Isomerase/*blood | 5 | 71.0 |
Radiotherapy Dosage | 2 | 1.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Dysentery, Amebic/parasitology | 2 | 100.0 |
Glucose-6-Phosphate Isomerase/analysis | 9 | 100.0 |
Hexokinase/analysis | 2 | 28.0 |
Malate Dehydrogenase/analysis | 4 | 36.0 |
Phosphoglucomutase/analysis | 4 | 40.0 |
Kinetics | 5 | 0.0 |
Molecular Weight | 3 | 0.0 |
Antigens, Viral/*immunology | 2 | 2.0 |
Chickenpox Vaccine | 2 | 100.0 |
Herpesvirus 3, Human/*immunology | 3 | 16.0 |
Immunity, Cellular | 2 | 0.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Lymphocyte Activation | 2 | 0.0 |
*Viral Envelope Proteins | 2 | 4.0 |
Viral Vaccines/*immunology | 2 | 8.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Entamoebiasis/*epidemiology/parasitology | 3 | 100.0 |
Rural Population | 2 | 2.0 |
Erythrocyte Membrane/analysis | 2 | 18.0 |
Membrane Proteins/blood | 2 | 5.0 |
Glycoproteins/*genetics | 2 | 1.0 |
Glucose-6-Phosphate Isomerase/*analysis | 6 | 85.0 |
Plasmodium vivax/*enzymology | 2 | 66.0 |
Thailand | 2 | 1.0 |
Electrophoresis | 4 | 1.0 |
India | 3 | 0.0 |
Erythrocytes/*enzymology | 8 | 1.0 |
Viral Proteins/*immunology | 2 | 5.0 |
Dogs | 3 | 0.0 |
Risk Assessment | 2 | 0.0 |
Platelet Aggregation Inhibitors/*therapeutic use | 2 | 8.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors | 2 | 10.0 |
Carboxylesterase | 2 | 5.0 |
*Genes | 4 | 1.0 |
Treatment Outcome | 2 | 0.0 |
Phosphoglucomutase/*analysis | 2 | 33.0 |
*Chromosomes, Human, 19-20 | 4 | 18.0 |
Dipeptidases/*genetics | 2 | 22.0 |
Heterozygote Detection | 2 | 0.0 |
Karyotyping | 2 | 0.0 |
Brazil | 4 | 1.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Granulocytes/enzymology | 2 | 16.0 |
Syndrome | 5 | 0.0 |
Blood Coagulation Factors/*physiology | 2 | 8.0 |
Membrane Proteins/physiology | 2 | 2.0 |
Platelet Membrane Glycoproteins | 3 | 6.0 |
Ristocetin/pharmacology | 2 | 1.0 |
von Willebrand Factor/*physiology | 2 | 3.0 |
Glucose-6-Phosphate Isomerase/deficiency | 2 | 66.0 |
Pyruvate Kinase/deficiency | 2 | 40.0 |
*Insect Vectors | 2 | 33.0 |
Israel | 2 | 1.0 |
Leishmania/classification/enzymology | 2 | 100.0 |
Leishmaniasis/parasitology/*transmission/veterinary | 2 | 100.0 |
Microtinae/parasitology | 2 | 100.0 |
Phlebotomus/*parasitology | 2 | 100.0 |
Phosphogluconate Dehydrogenase/analysis | 2 | 40.0 |
Rodent Diseases/parasitology | 2 | 100.0 |
Amebiasis/*epidemiology | 2 | 100.0 |
Entamoeba histolytica/*enzymology | 2 | 66.0 |
*Genes, Structural | 2 | 0.0 |
Japan | 4 | 0.0 |
Entamoeba/enzymology | 2 | 100.0 |
Mexico | 3 | 3.0 |
Pilot Projects | 2 | 0.0 |
Glucosephosphate Dehydrogenase Deficiency/*genetics | 2 | 2.0 |
Lupus Erythematosus, Systemic/immunology | 2 | 1.0 |
Leishmaniasis/parasitology | 2 | 100.0 |
Carcinoembryonic Antigen/*analysis | 2 | 3.0 |
Hybrid Cells/enzymology | 2 | 3.0 |
Anemia, Hemolytic/*enzymology | 2 | 40.0 |
Immunodiffusion | 2 | 0.0 |
*Glucose-6-Phosphate Isomerase | 2 | 100.0 |
*Polioviruses | 2 | 100.0 |
Metabolism, Inborn Errors/*complications/epidemiology/genetics | 2 | 100.0 |
